Stock Analysts’ updated eps estimates for Friday, August 18th:

AllianceBernstein Holding L.P. (NYSE:AB) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “ALLIANCE CAP MANAGEMENT L.P. provides diversified investment management services, primarily to pension funds, endowments, foreign financial institutions, and to individual investors. “

Addus HomeCare Corporation (NASDAQ:ADUS) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “ADDUS HOMECARE is a comprehensive provider of a broad range of social and medical services in the home. The company’s services include personal care and assistance with activities of daily living, skilled nursing and rehabilitative therapies, and adult day care. Its consumers are individuals with special needs who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. Its payor clients include federal, state and local governmental agencies, the Veterans Health Administration, commercial insurers and private individuals. Addus operates its business through two divisions, home & community services and home health services. The home & community services are social, or non-medical, in nature and include assistance with bathing, grooming, dressing, personal hygiene and medication reminders, and other activities of daily living whereas the home health services are medical in nature and include physical, occupational and speech therapy, as well as skilled nursing. “

ArQule (NASDAQ:ARQL) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company’s lead ACT program, based on the E2F-1 pathway, is partnered with Roche. “

Grupo Aeroportuario del Sureste, S.A. de C.V. (NYSE:ASR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $224.00 price target on the stock. According to Zacks, “Grupo Aeroportuario del Sureste is a Mexican airport operator with concessions to operate, maintain and develop the airports of Cancun, Merida, Cozumel, Villahermosa, Oaxaca, Veracruz, Huatulco, Tapachula and Minatitlan in the southeast of Mexico. “

Asure Software (NASDAQ:ASUR) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Asure Software Inc., formerly Forgent Networks, Inc., is a provider of Web-based workforce management solutions. It offers Web-based workforce management solutions that enable organizations to manage their office environment, as well as their human resource and payroll processes. The Company offers its workforce management solutions under two product lines: NetSimplicity and iEmployee. Asure’s suite includes products to optimize workforce time and attendance tracking, benefits enrollment and tracking, pay stubs and W2 documentation, expense management, meeting and event management, and asset tracking. The company delivers easy-to-use, easy-to-deploy software products that serve small and medium-sized organizations and divisions of Fortune and Global 1000 enterprises. It focuses on developing products that deliver enterprise-class productivity enhancements at an affordable price such that any size organization can enjoy the benefits of its solutions. “

Anavex Life Sciences Corp. (NASDAQ:AVXL) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company’s proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. “

Abraxas Petroleum Corporation (NASDAQ:AXAS) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Abraxas Petroleum Corporation is an independent energy company engaged primarily in the acquisition, exploration, exploitation and production of crude oil and natural gas. They seek to complement their acquisition and development activities by selectively participating in exploration projects with experienced industry partners. “

AXT (NASDAQ:AXTI) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $8.50 price target on the stock. According to Zacks, “AXT, Inc., designs, develops, manufactures and distributes high-performance compound semiconductor substrates, as well as opto-electronic semiconductor devices such as high-brightness light emitting devices, and vertical cavity surface emitting lasers. “

Build-A-Bear Workshop (NYSE:BBW) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Build-A-Bear Workshop is the leading and only national company providing a make your own stuffed animal interactive retail-entertainment experience. “

Bioverativ (NASDAQ:BIVV) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. “

Caleres (NYSE:CAL) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Caleres, Inc. is a footwear retailer and wholesaler. The Company is involved in the operation of retail shoe stores and e-commerce Websites as well as the design, sourcing and marketing of footwear for women and men. Its operating segment consists of Famous Footwear and Brand Portfolio. The company brands include Nike, Skechers, Bearpaw, Converse, Vans, New Balance, adidas, Asics, Sperry and Sof Sole, LifeStride, Dr. Scholl’s, Fergalicious, Naturalizer and Carlos. Caleres, Inc., formerly known as Brown Shoe Company, Inc., is headquartered in St. Louis, Missouri. “

Donaldson (NYSE:DCI) had its hold rating reaffirmed by analysts at Stifel Nicolaus. They currently have a $48.00 price target on the stock.

Infosys Limited (NYSE:INFY) had its hold rating reissued by analysts at Stifel Nicolaus. The firm currently has a $15.50 price target on the stock.

Kimbell Royalty (NYSE:KRP) had its buy rating reiterated by analysts at Stifel Nicolaus. The firm currently has a $19.00 target price on the stock.

Lindsay Corporation (NYSE:LNN) had its hold rating reaffirmed by analysts at Stifel Nicolaus. The firm currently has a $76.00 price target on the stock.

Paychex (NASDAQ:PAYX) had its hold rating reiterated by analysts at Stifel Nicolaus. The firm currently has a $61.00 price target on the stock.

Suburban Propane Partners, L.P. (NYSE:SPH) had its hold rating reiterated by analysts at Stifel Nicolaus. The firm currently has a $25.00 price target on the stock.

Tallgrass Energy GP, (NYSE:TEGP) had its buy rating reiterated by analysts at Stifel Nicolaus. Stifel Nicolaus currently has a $31.00 price target on the stock.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.